Metformin News and Research RSS Feed - Metformin News and Research

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.
Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Researchers have shown that the glucose-lowering drug liraglutide safely and effectively decreases the overall risk of heart attack, stroke, or cardiovascular death for people with type 2 diabetes. [More]
Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Empagliflozin has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
New research reveals advances that could change gynecologic cancer standard-of-care treatments

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology. [More]
New NPS MedicineWise program aims to help health professionals improve diabetes management

New NPS MedicineWise program aims to help health professionals improve diabetes management

A new educational program aims to help health professionals keep up to date with the latest evidence on second and third line medicines for lowering blood glucose. [More]
Cardioprotective effect proposed for metformin

Cardioprotective effect proposed for metformin

A large retrospective analysis suggests that metformin could be cardioprotective in insulin-dependent patients with Type 2 diabetes. [More]
Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Among the women inducted into the University of Kansas Hall of Fame on April 14, 2016, was Carol Fabian, MD. Fabian, a professor of medicine at the University of Kansas Medical Center and director of the Breast Cancer Prevention Center at The University of Kansas Cancer Center, is a nationally recognized oncologist and a pioneer in in the field of breast cancer research. [More]
Clinical study shows sitagliptin drug not effective in treating NAFLD

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. [More]
Oral regimens could offer simple solution for severe hyperglycaemia

Oral regimens could offer simple solution for severe hyperglycaemia

Study findings indicate that oral treatments could offer a simpler alternative to upfront insulin for patients who have severe hyperglycaemia at the time of diagnosis with Type 2 diabetes. [More]
New fruit fly model study reveals metabolic pathway that can be targeted to treat FXS patients

New fruit fly model study reveals metabolic pathway that can be targeted to treat FXS patients

Fragile X syndrome (FXS) is the most common genetically inherited cause of intellectual disability in humans. New research shows how the hormone insulin -- usually associated with diabetes -- is involved in the daily activity patterns and cognitive deficits in the fruitfly model of FXS, according to a new study from the Perelman School of Medicine at the University of Pennsylvania published online this month in Molecular Psychiatry in advance of the print issue. [More]
GLP-1 receptor agonist may benefit high-risk diabetes

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes. [More]
New clinical study to evaluate inexpensive drug to prevent type 1 diabetes

New clinical study to evaluate inexpensive drug to prevent type 1 diabetes

A clinical study evaluating a new hypothesis that an inexpensive drug with a simple treatment regimen can prevent type 1 diabetes will be launched in Dundee tomorrow. [More]
Exercise can lower blood glucose levels among patients taking metformin

Exercise can lower blood glucose levels among patients taking metformin

Exercise can help enhance the effects of blood glucose-lowering medication, according to an award-winning study by a University of Georgia graduate student. [More]
Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Research from Rutgers Cancer Institute of New Jersey examining difficult to treat cancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in the body. [More]
Metabolic syndrome treatment benefits MS patients

Metabolic syndrome treatment benefits MS patients

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report. [More]
Drug combination improves glucose control in Type 2 diabetes patients

Drug combination improves glucose control in Type 2 diabetes patients

A multinational clinical trial led by UT Southwestern Medical Center and others found that injection of a new long-acting insulin combined with another drug improves glucose control in patients with Type 2 diabetes and, additionally, is associated with weight loss. [More]
IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

More than two-thirds of all type-2 diabetes patients do not achieve good control of their disease with the first-line medication metformin combined with second-line insulin shots. [More]
Community-based weight management program more effective in preventing prediabetes than self-initiated program

Community-based weight management program more effective in preventing prediabetes than self-initiated program

A new randomized controlled study conducted by Indiana University School of Medicine researchers and published online today in the American Journal of Public Health found that adults with prediabetes who followed a nationally-available weight management program with a prediabetes-specific component, Weight Watchers, lost significantly more weight and experienced better blood glucose control than those following a self-initiated program using supplemental counseling materials. [More]
MGH study reveals effects of obesity on pancreatic and breast cancer

MGH study reveals effects of obesity on pancreatic and breast cancer

Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression. [More]
Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc., has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.'s Glumetza HCl ER Tablets, 500 mg and 1000 mg. [More]
Advertisement
Advertisement